Patent Application
20070248630
In one aspect, the invention provides pharmaceutical formulations that are suitable for iontophoresis and that provide enhanced iontophoretic delivery of MTX to a patient, preferably a human patient, in need of treatment.
Methotrexate (MTX) is a folic acid antagonist with antineoplastic activity that is useful in the treatment of psoriasis and rheumatoid arthritis. It is generally administered by oral or parenteral route for the treatment of psoriasis. When administered systemically over prolonged periods, it may produce side effects like nausea, vomiting, fatigue, anemia headache, leukopenia, thrombocytopenia and hepatic toxicity. Iontophoretic delivery of MTX can reduce such side effects by delivering it directly to the diseased psoriatic skin rather than systemically. Methotrexate has three pKa's (5.6, 3.8, and 4.8); it is negatively charged at physiological pH and was thus delivered by cathodal iontophoresis by means of electrorepulsion. MTX delivery was first studied at various buffer strengths and at different drug concentrations. Optimum ionic strength and drug concentration were selected and the effect of current density and time of application was studied.
Thus, the invention relates to the iontophoretic delivery of MTX. In a preferred embodiment, the MTX is formulated at a pH between 7 and 8 (e.g., 7.4). While it is preferred to not use buffers due to the possible competing ion effect, buffers can be used. Phosphate buffer is preferred. Preferably the ionic strength of the buffer is at least about 0.1M, such as about 0.25M. Preferably, the concentration of MTX in the formulation is at least about 1 mg/ml, such as at least about 8 mg/ml, preferably at least about 10 to 25 mg/ml, such as between 10 to 15 or 20 mg/ml.
A formulation of the invention is preferably a viscous formulation. As used herein, the term “viscous formulation” includes colloidal and gel formulations, such as a viscous formulation having a viscosity of greater than about 500 cp at 25 degrees Celsius. A viscosity modifying agent can be added to the formulation to achieve the desired viscosity. The pharmaceutically acceptable carrier or excipient may comprise about 0.1 to 10 weight percent of a viscosity modulating agent. As used herein, the term “pharmaceutically acceptable carrier or excipient” means any non-toxic diluent or other formulation auxiliary that is suitable for use in iontophoresis. Examples of pharmaceutically acceptable carriers or excipients include but are not limited to: diluents such as water, or other solvents, cosolvents; solubilizing agents such as sorbital and glycerin; buffers such as, for example, phosphate buffer solutions; pharmaceutically acceptable bases; and viscosity modulating agents such as cellulose and its derivatives.
As used herein the term “target tissue” includes the patient's dermis, epidermis, nails, mucocutaneous membranes including, but not limited to, the eye and the body cavity and canal sites such as mouth, ear, nose, vagina, and rectum.
The viscosity of the viscous formulation may be controlled by a viscosity modulating agent. A viscosity modulating agent includes any agent that is capable of modulating the viscosity of a gel. Viscosity modulating agents useful in the practice of the invention include but are not limited to, ionic and non-ionic, high viscosity, water soluble polymers; crosslinked acrylic acid polymers such as the “carbomer” family of polymers, e.g., carboxypolyalkylenes that may be obtained commercially under the Carbopol® trademark; hydrophilic polymers such as polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers, and polyvinylalcohol; cellulosic polymers and cellulosic polymer derivatives such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, methyl cellulose, carboxymethyl cellulose, and etherified cellulose; gums such as tragacanth and xanthan gum; sodium alginate; gelatin, hyaluronic acid and salts thereof, chitosans, gellans or any combination thereof. It is preferred that non-acidic viscosity enhancing agents, such as a neutral or basic agent be employed in order to facilitate achieving the desired pH of the formulation. If a uniform gel is desired, dispersing agents such as alcohol, sorbitol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing, or stirring, or combinations thereof. In one embodiment, the viscosity enhancing agent can also provide the base, discussed above.
In one preferred embodiment, the viscosity modulating agent is cellulose that has been modified such as by etherification or esterification. One such etherified cellulose polymer is sold under the trademark Natrosol® (Hercules-Aqualon, Wilmington, Del.).
Preferred iontophoretic delivery devices useful with the compositions and methods of the invention include but are not limited to those described in U.S. Pat. Nos. 6,148,231, 6,385,487, 6,477,410, 6,553,253, and U.S. Patent Publication Numbers 2004/0111051, 2003/0199808, 2004/0039328, 2002/0161324, and U.S. Application Ser. No. 60/743,528, all incorporated herein by reference. A preferred applicator which has been developed for use with a device for electrokinetically delivering a medicament to a treatment site comprising an applicator head having opposite faces and including an active electrode and a porous pad (such as a woven or non-woven polymer, for example, polypropylene, pad); a margin of the applicator head about the active electrode having a plurality of spaced projections therealong; the porous pad and the applicator head being ultrasonically welded to one another about the margin of the head with the electrode underlying the porous pad; and a medicament or a medicament and an electrically conductive carrier therefor carried by the porous pad in electrical contact with the electrode. Alternatively or additionally, the applicator has been developed for use with a device for electrokinetically delivering a medicament to a treatment site comprising an applicator head having opposite faces and including an active electrode and a porous pad overlying the active electrode; a medicament or a medicament and an electrically conductive carrier therefor carried by the pad and in electrical contact with the electrode; a lid overlying the porous pad on a side of the porous pad remote from the electrode and releasably secured to the applicator head; and the lid comprising layers of different materials and including one or more tabs, one of the layers of the lid and the tab being formed of a metallic material, at least a portion of an interface between the metallic material of the tab and the metallic material of the lid having a discontinuity. In another embodiment, the lid may be an oversided disc having a rim constituting an annular tab. Additionally or alternatively, the applicator which has been developed for use with a device for electrokinetically delivering a medicament to a treatment site comprising an applicator head having opposite first and second faces and including an active electrode and a porous pad overlying said electrode; a medicament or a medicament and an electrically conductive carrier therefor carried by the pad; a margin of the cartridge about the active electrode and a margin of the porous pad being secured to one another; the active electrode having a first portion thereof exposed through the first face of the applicator head remote from the porous pad; and another portion of the active electrode being exposed to the porous pad along the second face of the applicator head for electrical contact with the medicament or the medicament and the electrically conductive carrier.
The formulations are preferably administered via iontophoresis. In a preferred embodiment, a current density of at least 0.02 mA/cm2 is applied, such as at least 0.5 mA/cm2. In a preferred embodiment, a flux of at least about 0.2 μg/cm2-hr, such as about 0.6 μg/cm2-hr, is achieved. The iontophoresis can be applied for a sufficient time to achieve an effective amount. In general, the time of application can be between about 5 and 60 minutes, such as about 30 minutes or less.
The following Examples further illustrate the present invention but should not be construed as in any way limiting its scope.
The delivery of MTX under 30 mins of iontophoresis (0.4 mA/cm2) was studied at buffer strengths 0.05-0.5 M and drug concentrations 10-20 mg/ml. The effect of current density and time of application on the delivery of MTX is studied by optimizing the full-factorial design. The current density (X1) and time of application (X2) are the independent factors chosen for the factorial design with 4 and 5 levels, respectively in the range of 0.05-0.5 mA (X1) and 10-120 mins (X2).
In vitro iontophoretic experiments (n≧3) were performed using freshly excised hairless rat skin mounted on vertical Franz diffusion cells with stratum corneum facing towards the donor chamber. The donor compartment contained 15 mg/ml of MTX in phosphate buffer of pH 7.4 (0.25 M) and the receptor compartment contained phosphate buffer of pH 7.4 (0.25 M) with 75 mM NaCl.
A silver-silver chloride electrode (cathode) was placed in the donor chamber and silver wire (anode) was placed in the receptor compartment. Samples were taken at periodic intervals and were analyzed by HPLC, using YMC RP 18 column. Mobile Phase was composed of monobasic sodium phosphate (10%) and Tris HCl buffer (90%). Flow rate was 1.5 ml/min and detection wavelength was 303 nm.
The cumulative amount of MTX delivered across hairless rat skin increased with decrease in ionic strength of the buffer (
The experimental data of the fractional factorial design is plotted as seen in
The predictions of the model have been verified by performing an experiment in the experimental region with current density 0.4 mA/cm2 and ITP for 30 mins. The cumulative amount of drug delivered was found to be in between the lower and upper 95% confidence level, thus establishing the validity of the model.
Screening studies were first used to select the buffer strength (0.25 M) and drug concentration (15 mg/ml). An increase in time of current application and/or current density led to increased delivery of MTX across the skin only for higher level settings. The maximal flux of about 0.6 μg/cm2-hr was obtained.
The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
This application claims the benefit of U.S. Provisional Application No. 60/793,679, filed on Apr. 20, 2006. The entire teachings of the above application are incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| 60793679 | Apr 2006 | US |
